NLRP3 and cystic fibrosis: Selective NLRP3 inhibition in vivo with MCC950 abrogated IL-1β release in the CF mice lungs (p < 0.0001), with consequent indubitably repressed airway inflammation and augmented elimination of Pseudomonas aeruginosa (p < 0.0001) [44,45].